clinical trial · NCT05935033
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
AbbVie·phase1·completed·n = 38
Hepatic ImpairmentEmraclidine
brief summary
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.
started
Jun 30, 2023
primary completion
Feb 21, 2025
completion
Feb 21, 2025
last updated
Apr 4, 2025
official title
A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment Compared With Adult Participants With Normal Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol